A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
for Down Syndrome
Drug: Nivolumab
209 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 1 - 30
Code: NCT04546399·Phase 2·Recruiting